You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cardiovascular conditions
  5. Structural heart defects

Vutrisiran for treating transthyretin amyloidosis with cardiomyopathy

  • Technology appraisal guidance
  • Reference number: TA1115
  • Published:  10 December 2025
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

28653-Vutrisiran-for-Transthyretin-Amyloid-Cardiomyopathy-V1.0-APR2024-NON-CONF.pdf (nihr.ac.uk)

This page was last updated: 15 July 2024

Back to top